Log In
Print this Print this

Biosimilar ranibizumab (FYB201)

  Manage Alerts
Collapse Summary General Information
Company Formycon AG
DescriptionBiosimilar of ranibizumab, a humanized mAb fragment against VEGF-A
Molecular Target Vascular endothelial growth factor A (VEGF-A)
Mechanism of ActionVascular endothelial growth factor A (VEGF-A) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat age-related macular degeneration (AMD)
Regulatory Designation
PartnerSanto Holding GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today